Document is current
Any future updates will be listed below
-
Authors
Holowatyj, Andreana N. https://orcid.org/0000-0001-8001-8793
Overman, Michael J.
Votanopoulos, Konstantinos I.
Lowy, Andrew M.
Wagner, Patrick
Washington, Mary K.
Eng, Cathy https://orcid.org/0000-0003-2335-0612
Foo, Wai Chin
Goldberg, Richard M.
Hosseini, Mojgan
Idrees, Kamran https://orcid.org/0000-0003-0911-4461
Johnson, Douglas B.
Shergill, Ardaman
Ward, Erin
Zachos, Nicholas C.
Shelton, Deborah
,
- License Information
-
More Information
Article History
Accepted: 12 December 2024
First Online: 20 February 2025
Competing interests
: A.N.H. is Chair of the Scientific Advisory Board for the Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation and is on the American Joint Committee on Cancer Lower Gastrointestinal Tract Expert Panel and the Peritoneal Surface Malignancies Consortium. A.N.H. reports receiving grants from the National Institutes of Health, American Cancer Society, ACPMP Research Foundation, Dalton Family Foundation and Pfizer. A.N.H. also reports receiving consulting fees from MJH Life Sciences and Bayer outside the submitted work. M.J.O. and K.I.V. are Scientific Advisory Board members for the ACPMP Research Foundation. M.J.O. reports receiving research funding from Takeda, Roche, Lilly, Merck, Medimmune, Bristol–Myers Squibb (BMS), Nouscom and Phanes. M.J.O. also reports consulting fees from Roche, Astellas, Medimmune, Merck, Amgen, Takeda, Janssen, Pfizer, Array, Gritstone, Simcere, Atreca and Bayer. K.I.V. reports receiving grants from the National Institutes of Health and ACPMP Research Foundation. K.I.V. also reports financial interests as the Chief Executive Officer and Founder of Applied Organoids. A.M.L. is a Medical Advisory Board member for the ACPMP Research Foundation and reports receiving grants from the Levine Family Chancellor’s Endowed Chair in Surgical Oncology, National Institutes of Health, and Department of Defense, as well as generous gifts from the estate of Elisabeth and Ad Creemers, the Euske Family Foundation, the Gastrointestinal Cancer Research Fund and the Peritoneal Metastasis Research Fund at the University of California, San Diego. P.W. reports receiving grants from the Pittsburgh Foundation and the ACPMP Research Foundation. R.M.G. reports personal fees from Adaptimmune, AstraZeneca, Bayer, Compass Therapeutics, Focal Medical, G1 Therapeutics, Genentech, GlaxoSmithKline, Haystack Oncology, Innovative Cellular Therapeutics, Merck, Sorrento Therapeutics, Taiho Oncology, Takeda, Valar Technologies and Wolters Kluwer Health outside the submitted work. R.M.G. also reports owning stock options in Focal Medical, Haystack Oncology and Compass Therapeutics. D.B.J. has served on advisory boards or as a consultant for AstraZeneca, BMS, The Jackson Laboratory, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Pfizer, Targovax and Teiko; has received funding from BMS and Incyte; and has patents pending for the use of MHC-II as a biomarker for immune checkpoint inhibitor response and for abatacept as treatment for immune-related adverse events. A.S. has served on advisory boards for Merus, Guardant, Pfizer, Regeneron/Sanofi and Catalyst Pharmaceuticals. A.S. also reports receiving funding (to the University of Chicago Medical Center) from Hutchison MediPharma, Takeda, Merck, Verastem Oncology, Turning Point Therapeutics, Gritstone, Bolt Therapeutics, BMS, Pfizer, Astellas, Oncologie, Macogenics, Seattle Genetics, Amgen, Daiichi, Lilly, Jacobio, Astrazeneca, Jazz Pharma and Agenus. N.C.Z. reports receiving grants from the National Institutes of Health, Department of Defense, and Eli Lilly and Company. D.S. is a volunteer Executive Director and Board member for the ACPMP Research Foundation. W.C.F., C.E., M.K.W., M.H., K.I. and E.W. declare no competing interests.
